prilocaine
Also known as ASTRA 1512, L-67, Prilotekal®, o-Methyl-alpha-propylaminopropionanilide, o-Methyl-2-propylaminopropionanilide, alpha-n-Propylamino-2-methylpropionanilide, Propitocaine, N-(2-Methylphenyl)-2-(propylamino)propanamide
Prilocaine () is a local anesthetic of the amino amide type first prepared by Claes Tegner and Nils Löfgren. In its injectable form (trade name Citanest), it is often used in dentistry. It is also often combined with lidocaine as a topical preparation for dermal anesthesia (lidocaine/prilocaine or EMLA), for treatment of conditions like paresthesia. As it has low cardiac toxicity, it is commonly used for intravenous regional anaesthesia (IVRA).
Chemical data
- Formula
- C13H20N2O
- Molecular weight
- 220.31 g/mol
- IUPAC name
- N-(2-methylphenyl)-2-(propylamino)propanamide
- SMILES
- CCCNC(C)C(=O)NC1=CC=CC=C1C
- InChIKey
- MVFGUOIZUNYYSO-UHFFFAOYSA-N
- XLogP
- 2.1
- Polar surface area
- 41.1 Ų
- H-bond donors
- 2
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Research
2,924 papers~2 min read
Article
7 sectionsContents
- Contraindications
- Combinations
- Compendial status
- Synthesis
- See also
- References
- External links
Prilocaine () is a local anesthetic of the amino amide type first prepared by Claes Tegner and Nils Löfgren. In its injectable form (trade name Citanest), it is often used in dentistry. It is also often combined with lidocaine as a topical preparation for dermal anesthesia (lidocaine/prilocaine or EMLA), for treatment of conditions like paresthesia. As it has low cardiac toxicity, it is commonly used for intravenous regional anaesthesia (IVRA).
== Contraindications == In some patients, ortho-toluidine, a metabolite of prilocaine, may cause methemoglobinemia, which may be treated with methylene blue. Prilocaine may also be contraindicated in people with sickle cell anemia, anemia, or symptomatic hypoxia.